Pain Relief – The Pharmacology of Analgesics and Non-Steroid Anti-Inflammatories (NSAIDs)

As pain, be it acute or chronic, can severely restrict the quality of life, humanity has been striving for pain relief since year zero. Painkillers (analgesics) are thus one of the most frequently ingested forms of medication. For that reason, knowledge of the effects and side effects of analgesics is essential during your medical studies and later work as a physician. The following article shall provide you with an overview of the most important painkillers.

The WHO Pain Relief Ladder for Pain Treatment

In 1986, the WHO (World Health Organization) compiled a plan for treating chronic pain, which orders the administration of oral analgesics (painkillers) according to their various potencies: First, apply weaker analgesics, and if the desired effect is not achieved move onto stronger analgesics; coanalgesics (see below) can be administered at each level. These levels of pain, initially only used to treat pain from tumors, are now applied in the...
treatment of other chronic pains as well.

**Level 1: Non-Opioid Analgesics**

The **non-opioid analgesics** of the first WHO level of pain include **paracetamol** (4 to 6 x 500 to 1000 mg per day), **naproxen** (2 x 500 mg per day), **diclofenac** (2 x 50 to 150 mg per day) and **ibuprofen** (2 to 3 x 800 mg per day). However, paracetamol is only slightly effective against bone, soft tissue and tumor pain as it is not antiphlogistic. Patients with a high risk of gastrointestinal complications should also take **proton pump inhibitors** (e.g., omeprazole).

The effects and side effects of said substances are described further below in the text.

**Level 2: Non-Opioid Analgesics Plus Low-Potency Opioids**

Administration of **low-potency opioids** along with the non-opioid analgesics occurs at the second of the WHO levels of pain. These include **dihydrocodeine** (2 to 3 x 60 to 180 mg per day), **tramadol** (2 to 3 x 100 to 300 mg) and **tilidine** (2 to 3 x 100 to 200 mg per day), all of which are administered as a **retarded compound**.

The low-potency opioids will be discussed in detail later. In case of very severe chronic pain, or insufficient effectiveness of low-potency opioids, you should switch to pain level three, but never combine the opioids of levels two and three, as this will weaken the effects of the pharmaceuticals.

**Note:** Opioids of levels two and three must not be combined with each other!

**Level 3: Non-Opioid Analgesics Plus High-Potency Opioids**

The third of the WHO levels of pain stipulates a combination of non-opioid analgesics and **high-potency opioids**. These include **morphine** (6 x 5 to 500 mg p.o. per day), **hydromorphone** (2 to 3 x 4 to 200 mg p.o. per day), **buprenorphine** (3 to 4 x 0.2 to 1.2 mg s.l. per day), **fentanyl** (0.6 to 12 mg transdermally) and **oxycodone** (2 to 3 x 10 to 400 mg p.o. per day). **Retarded morphine** is the medication of choice, **non-retarded** is primarily ingested as **required medication** for **breakthrough** or **peak pain**. For dysphagia, severe constipation or other intestinal absorption disorders, fentanyl or buprenorphine may also be administered as a **transdermal patch** (TTS = transdermal therapeutic system).

Opioids are ingested at specific increments that should not be shortened as, otherwise, the patient runs the risk of **accumulation** of the agents. Else, the dosage should be increased upon experiencing pain within the interval.

**Note:** Pain treatment is performed “by the mouth” (oral), “by the ladder” (according to the levels of pain) or “by the clock” (fixed intervals).

The effects and side effects of the high-potency opioids are discussed in the article “Anaesthesia”.

<table>
<thead>
<tr>
<th>WHO Levels of Pain</th>
<th>Level 1</th>
<th>Level 2</th>
<th>Level 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-opioid analgesics</td>
<td>Low-potency opioids + non-opioid analgesics</td>
<td>High-potency opioids + non-opioid analgesics</td>
<td></td>
</tr>
<tr>
<td>Coanalgesics and non-medication measures</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Non-Opioid Analgesics

**Non-opioid analgesics** describe pain medications that do not interact with the **opioid receptors** but rather perform a pain-inhibiting effect in a different manner.

Antipyretic Analgesics as Inhibitors of Cyclooxygenases

**Antipyretic** analgesics lower fever and alleviate pain by inhibiting the **cyclooxygenases**.

The cyclooxygenases are key enzymes in the formation of **arachidonic acid derivatives** (eicosanoids). Uninhibited, they catalyze the formation of **prostaglandin G2** and **prostaglandin H2** from the **arachidonic acid**, which ultimately produces **prostaglandin**, **prostacyclin**, and **thrombaxane** due to the effects of other enzymes. Along with **physiological** reactions, these also facilitate **pathophysiological** processes, such as fever, inflammation, and pain.

![Diagram of cyclooxygenases](image: COX-1 and COX-2 convert arachidonic acid to the intermediate PGH2, which is then metabolized by specific distal enzymes to produce the different PGs and thromboxane. NSAIDs inhibit both COX forms, while the coxibs selectively inhibit COX-2. by BQUB14-Msanjose. License: CC-BY-SA-4.0)

The cyclooxygenases are present as isoenzymes **COX-1** and **COX-2**. **COX-1** is **constitutively** expressed in many cells of the human body, including the cells of the gastric mucosa, where it facilitates the **synthesis of PGE2** (prostaglandin E2) to protect the mucosa. This enzyme is thus responsible for many **physiological** processes.

**COX-2**, however, is only constitutively present in a few cells (kidney, brain, vessels) and
is thus primarily an inducible enzyme. The expression thereof is greatly increased by inflammations, trauma or ischemia, so that pathological processes (fever, inflammation, pain), among others, are triggered.

Due to the presence of cyclooxygenases as isoenzymes, there are two ways to inhibit these enzymes: selective and non-selective inhibition.

Non-Selective COX Inhibitors

The non-selective inhibitors of the cyclooxygenases include antipyretic analgesics with an antiphlogistical (inflammation-inhibiting) effect (acid analgesics, NSAR = non-steroidal antirheumatics) and those with no antiphlogistical effect (non-acid analgesics).

The acid analgesics are thus additionally antiphlogistical as they easily penetrate inflamed tissue—unlike the non-acid analgesics—and can often exercise their effect there. The most important acid analgesics are acetylsalicylic acid (ASA), ibuprofen and diclofenac, while paracetamol and metamizole are non-acid analgesics. With the exception of ASA, which irreversibly inhibits cyclooxygenases, all of these substances are competitive inhibitors.

Side effects of non-selective COX inhibitors

As the cyclooxygenases are present in many of the body’s cells, they have a wide range of side effects:

- **Gastrointestinal tract:** The most common side effects include dyspeptic symptoms, gastroduodenal ulcers (due to decreased prostaglandin synthesis and increased leukotriene synthesis and accumulation of the acid analgesics in the gastric mucosa); proton pump inhibitors are suitable for prevention.

  ![Gastric Ulcer Antrum](image)

  **Kidney:** Sodium retention (result: increase in preload, edema of the legs), decreased diuresis, hyperkalemia (result: cardiac arrhythmias); CAVE in patients of advanced age, with diabetes mellitus or limited kidney function!
- **CNS:** Headaches, vertigo, hearing and vision impairment.
- **Respiratory tract:** Bronchoconstriction (due to decreased prostaglandin synthesis and increased leukotriene synthesis), analgesic asthma, “aspirin” or “Samter’s triad”: nasal polyp + intrinsic asthma + sinusitis.
- **Pregnancy:** Contraction inhibition with subsequent bradytocia, premature closing of the ductus Botalli.
- **Blood coagulation:** Thrombocyte aggregation inhibition.
- **Hypersensitivity reactions:** Anaphylactic shock, pseudo allergic reactions, skin reactions.

**Acetylsalicylic acid (ASA)**

ASA is one of the oldest and most well-known painkillers, and its effectiveness **depends on its dosage**:

- From < 30 mg/d: Thrombocyte aggregation inhibition
- Up to 2 to 3 g/d: Analgesic and antipyretic
- 2 to 4 g/d: Antiphlogistic

ASA is thus administered to lower fever and for general states of pain; yet in high doses, it can also be used to treat acute and chronic inflammation (e.g., gout, rheumatic fever, osteoarthritis, rheumatoid arthritis).

The COX-1 (catalyst of thrombaxane formation in thrombocytes which activates the thrombocyte aggregation inhibition) must be at least 95% inhibited for thrombocyte aggregation inhibition to be present. This is only the case with the acid analgesics, whereby ASA is the only analgesic that irreversibly inhibits the cyclooxygenases via acetylation. As thrombocytes have no nucleus and thus cannot emulate COX-1; the thrombocyte aggregation inhibition lasts for eight to ten days (corresponds to the lifespan of the platelets) and can be used therapeutically: prophylaxis of thromboses and embolisms, treating CHD, PAD and cerebrovascular diseases as well as secondary prophylaxis of heart attack or stroke.

**CAVE:** ASA must be discontinued at least seven days before an operation as otherwise there is a greater tendency to bleed!

The side effects of ASA correspond to the general side effects of the non-selective COX inhibitors, whereby the gastrointestinal symptoms take priority.
The “aspirin triad” (also known as **Samter’s triad**) may appear as a special oversensitivity reaction to ASA (but also other NSAR), which results in nasal polyps (polyposis nasi), **asthma** and **sinusitis**. **Bronchoconstriction** stemming from an imbalance between **bronchodilatory prostaglandins** and **bronchoconstriction leukotrienes** results in so-called **analgesic asthma**. There is also a greater **risk of bleeding** from ingestion of ASA due to thrombocyte aggregation inhibition.

**Note:** Samter’s triad and analgesic asthma are side effects of ASA.

Another special side effect of ASA is **Reye’s syndrome**, which can appear as a result of an infection (chickenpox, influenza) in children under 16. This results in **encephalopathy** and **fatty liver cell degeneration**. This is symptomatically expressed by vomiting, unconsciousness, cerebral edema and spasms as well as increased ammonia levels, increased transaminases, and coagulation disorders as a sign of **liver insufficiency**. With a **lethality rate** of 25 to 50%, ASA should thus only be used conservatively in children.

Separating **acetyl** from ASA results in **salicylic acid**, which is expelled **renally**. As this has an **acidic pH value**, expulsion can be accelerated via **alkalization** of the urine (e.g., by administering bicarbonate). For instance, this is required in the event of intoxication with ASA.

**Ibuprofen**
Another example of an NSAR is ibuprofen, which functions as a **reversible inhibitor** of cyclooxygenases. Just like ASA, it is **analgesic**, **antipyretic** and **antiphlogistic** in higher doses (single dose: max. 800 mg, maximum daily dosage 2400 mg). Unlike the other acid analgesics, its gastrointestinal side effects are rather minor, which makes it more gastrally tolerable. Another advantage is that it **does not accumulate** after multiple ingestions, making an overdose unlikely. Simultaneous ingestion of ASA and ibuprofen lowers the inhibiting effect of ASA on **thrombocyte aggregation** as the substances compete for the catalytic center of the COX-1.

**Diclofenac**

The NSAR **diclofenac** alleviates pain more effectively than ASA or ibuprofen. The side effects correspond to the characteristically undesired effects of the non-selective COX inhibitors, with **gastrointestinal discomfort** being the most significant.

**Paracetamol**

**Paracetamol** is the most frequently used **analgesic** and **antipyretic**. Because of its low side effect profile (only very few gastrointestinal side effects), it is the **medication of choice** for pain and fever in **children** and is also permitted for use by **pregnant women**. Unlike the acid analgesics, it is **not antiphlogistic** and can be administered as juice, tablets, suppositories or an injection.
Paracetamol is mainly metabolized in the liver by glucuronidation and sulfation. Reactive intermediate products, among others, form upon the breakdown of the medication, and these are inactivated by linkage to glutathione. In the event of an overdose of paracetamol (> 7.5 g per day), the glutathione reserves are exhausted, the reactive metabolites are no longer inactivated and bind with liver cell proteins. This results in liver cell necrosis with the risk of liver failure. The sulfhydryl group donor N-acetylcysteine is a life-saving antidote.

**Note:** Paracetamol is hepatotoxic in excess doses!

Due to the potential liver toxicity, paracetamol should not be administered to patients with severe liver dysfunction, glucose-6-phosphate-dehydrogenase deficiency (decreased glutathione reserves!) and alcoholism.

An overdose of paracetamol may also have a toxic effect on the kidneys.

**Metamizole**
The **pyrazolone derivative metamizole** is also known as **novaminsulfon** and is the most effective non-opioid analgesic. In addition to its **analgesic** and **antipyretic** potency, it is the only **spasmolytic** (anticonvulsive) non-opioid analgesic and is thus administered to counter very severe pain, tumorous pain, colics and high fever.

It may be administered **orally, rectally or intravenously**, but too rapid an IV injection may result in a **shock reaction** with a possibly **lethal** result.

**CAVE:** Always slowly inject metamizole intravenously (< 1 ml/min)!

**Gastrointestinal** side effects rarely arise after ingestion of metamizole. However, various **oversensitivity reactions** such as **leukopenia**, **exanthema** and minor to severe **anaphylactic** reactions (see above) do occur.

**Agranulocytosis**, in which antibodies are formed to target **granulocytes**, is the most severe side effect. This results in cytotoxic immune reactions with high fever, sore throat, difficulties swallowing, **mucosal ulcers** in the mouth, pharynx and less commonly in the genitals and anal region and, ultimately, a systemic reaction with **sepsis** and possible death. Should there be suspicion of agranulocytosis, administration of metamizole must immediately be discontinued. This is followed by the administration of **antibiotics** and perhaps also **transfusion** of granulocytes. In order to prevent agranulocytosis, or to treat it in time, **regular blood samples** are required during long-term treatment with metamizole.

**Note:** An important side effect of metamizole is **agranulocytosis**. It is primarily metabolized in the liver and expelled through the kidneys.

**Contraindications** for the administration of metamizole include **acute hepatic porphyria** and hereditary **glucose-6-phosphate dehydrogenase** deficiency.

**Note:** Due to the life-threatening side effects of metamizole, a very strong indication has to be present!

### List of the Most Common Non-Selective COX Inhibitors

<table>
<thead>
<tr>
<th>Agent</th>
<th>Dosage (p.o.)</th>
<th>Duration of effect &amp; administration</th>
<th>Effect</th>
<th>Side effect</th>
<th>Contraindication</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASA (acidic)</td>
<td>0.5 to 1 g; max. daily dose: 6 g</td>
<td>6 to 8 h, half-life 15 min.; oral, IV</td>
<td>Analgesic, antipyretic, antiphlogistic, thrombocyte aggregation inhibition</td>
<td>Analgesic asthma, Samter’s triad, elevated risk of bleeding, Reye’s syndrome, gastrointestinal complaints</td>
<td>Pregnancy (esp. 3rd trimester), duodenal ulcers, hemorrhagic diathesis, renal insufficiency</td>
</tr>
<tr>
<td>Ibuprofen</td>
<td>200 to 400 mg; max. daily dose: 1200 mg</td>
<td>Up to 6 h, half-life 2 h; oral, rectal, IV, topical, dermal</td>
<td>Analgesic, antipyretic, antiphlogistic</td>
<td>Headaches, vertigo, tinnitus, gastrointestinal complaints (although more tolerable than other NSAR or ASA)</td>
<td>See ASA</td>
</tr>
<tr>
<td>Drug</td>
<td>Dosage/Type</td>
<td>Duration</td>
<td>Half-life</td>
<td>Formulations</td>
<td>Effects</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
<td>----------</td>
<td>-----------</td>
<td>--------------</td>
<td>---------</td>
</tr>
<tr>
<td>Diclofenac</td>
<td>25 to 150 mg</td>
<td>Up to 6 h</td>
<td>1 to 2 h</td>
<td>Oral, rectal, IV, transdermal, as gel and as eye drops</td>
<td>Analgesic, antipyretic, antiphlogistic</td>
</tr>
<tr>
<td>Paracetamol</td>
<td>0.5 to 1.0 g (adults); 10 to 15 mg/kg (children)</td>
<td>6 to 8 h</td>
<td>2 h</td>
<td>Oral, rectal, IV</td>
<td>Analgesic, antipyretic</td>
</tr>
<tr>
<td>Metamizole</td>
<td>0.5 to 1 g (max. daily dose: 4 g)</td>
<td>6 to 8 h</td>
<td></td>
<td>Oral, rectal, IV</td>
<td>Analgesic, antipyretic, spasmolytic</td>
</tr>
</tbody>
</table>

**Selective COX-2 Inhibitors**

**Selective COX-2 inhibitors**, also known as *coxibs*, selectively inhibit COX-2 as the name implies. The gastroprotective prostaglandin-producing COX-1 is not inhibited, which leads to a reduced **side effect profile** with the only rare incidence of **gastrointestinal complaints**.

*Celecoxib* (p.o.) and *Etoricoxib* (p.o.) are available as substances for treating *arthrosis* and *rheumatoid arthritis* and *parecoxib* (IV, i.m.) for treating postoperative pain. However, the coxibs are not without side effects: Long-term use thereof may lead to **thrombotic cardiovascular events** (heart attack or stroke). For that reason, the objective should be a low dosage and a brief treatment period.

**Note:** The cardiovascular risk of coxibs increases with dosage and duration!

Selective COX-2 inhibitors should not be administered to patients with oversensitivity toward coxibs or sulfonamides, inflammatory intestinal diseases, CHD, PAD, stroke, cardiac insufficiency, *gastroduodenal ulcers* or severe liver and kidney dysfunction.

**Low-Potency Opioid Analgesics**

Opioids are discussed in more detail in the article “Anaesthesia”; yet a brief overview of the low-potency opioids is provided below.

The **low-potency opioids** tilidine, dihydrocodeine, codeine, and tramadol are designed to alleviate moderately severe to severe pain. Compared to the reference substance morphine, they are less effective, meaning that they have a lower **analgesic** (relative) **potency** (RP < 1).

If the dosage of low-potency opioids is raised to a certain point, the same level of pain relief as morphine can be achieved. This is referred to as **maximum achievable analgesia**. Each additional dosage increase would then only lead to amplification of the side effects, while the analgesic effect can no longer be enhanced. This is not the case with high-potency opioids.
**Tramadol** has 0.1 to 0.2 times the analgesic potency of morphine. Its major side effects are nausea and vomiting, while constipation and hypoventilation occur only rarely. It has a duration of action of four to six hours and can be applied orally, intravenously, intramuscularly or rectally.

**Dihydrocodeine** and **codeine** have a relative potency of 0.3 and are administered as antitussives due to their cough-relieving effect. They are active for approximately eight to twelve hours and are administered orally.

**Tilidine** has an analgesic potency of 0.2 and a duration of action of approximately three hours. Hepatic conversion yields the active metabolite nortilidine. **Tilidine** is available in combination with the opioid-antagonist naloxone. If a normal dosage of this compound is ingested orally, the naloxone portion is inactivated by the first-pass effect, so that nortilidine can exercise its effect. However, if it is improperly injected intravenously, naloxone will exercise its effect: As an antagonist to the opioids’ receptor, it prevents an addictive effect and the feared hypoventilation.

**Coanalgesics**

Medications that usually have a different indication, but actually can alleviate pain in combination with analgesics or even on their own, are administered as coanalgesics for adjuvant pain therapy. These include the following substances, among others:

- **Antidepressants**: increase in the serotonin and noradrenaline concentration in the synaptic cleft of the descending antinociceptive neuronal system; best analgesic effect with tricyclic antidepressants (amitriptyline, imipramine, clomipramine, doxepin); application: chronic and neuropathic pain, lower dosage than necessary for
the antidepressant effect; other substances: **bupropion, venlafaxine, duloxetine**.
- **Anticonvulsants**: blockage of sodium channels (carbamazepine, lamotrigine, topiramate) and calcium channels (gabapentin, pregabalin) in the CNS; application: neuropathic pain (e.g., trigeminal neuralgia).
- **Glucocorticoids**: antiphlogistic, antipyretic and anti-edematous; application: neuropathic and nociceptor pain (e.g., pain due to metastases).
- **Bisphosphonates**: application: treating osteoporosis and for osteolytic bone metastases.

**Non-Steroid Anti-Inflammatories (NSAIDs)**

- ASA and others of the same class
- Ibuprofen is a relatively low potency, short-acting example of the family
- Inhibit the action of cyclooxygenase enzymes (COX-1 and COX-2) and reduce the production of prostaglandins which are present in inflamed tissues
- Analgesia by reducing prostaglandin synthesis
- Reduce the recruitment of leukocytes which produce inflammatory mediators
- Directly inhibit the release of prostaglandins in the dorsal horn
- Side effects: gastric hemorrhage, platelet dysfunction, renal toxicity

**Specific drugs**

- ASA — relatively short-acting, the little negative effect upon the kidney
- Acetaminophen — reduces central prostaglandin synthesis — no real anti-inflammatory effect — no renal effects — overdose can cause acute liver failure

**Ibuprofen — relatively short-acting**

- Naproxen, ketorolac (systemic), diclofenac, and others — relatively long-acting — all have negative renal and gastric effects — likely also have cardiac effects
- COX-2 inhibitors were introduced with the expectation of fewer side effects (particularly gastric) but caused an increased incidence of ischemic cardiac events (myocardial infarctions and death) and were withdrawn from the market

**Review Questions**

Correct answers can be found below the references.

1. **The WHO pain relief ladder...**
   - A. ...was developed to treat acute pain.
   - B. ...consists of five different levels that determine the dosage increase of analgesics.
   - C. ...recommends a combination of opioids from levels two and three.
   - D. ...stipulates fixed intervals for high-potency opioids.
   - E. ...categorically excludes coanalgesics as an additional medication.

2. **Which of the following statements about non-opioid analgesics is true?**
   - A. Paracetamol works as a selective COX-2 inhibitor.
B. Paracetamol and metamizole are antipyretic, analgesic and antiphlogistic.
C. Metamizole is the first medication of choice for lowering fever and relieving pain in children.
D. One side effect of parecoxib is Reye’s syndrome.
E. Coxibs can lead to thrombotic cardiovascular events.

3. Which substance does not alleviate pain?
   A. Amitriptyline
   B. Flucloxacillin
   C. Tildine
   D. Pentagabin
   E. Dihydrocodeine

References

doi:10.1007/bf03320167


Correct answers: 1D, 2E, 3B

Legal Note: Unless otherwise stated, all rights reserved by Lecturio GmbH. For further legal regulations see our legal information page.